Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.
Curtin NJ, Barlow HC, Bowman KJ, Calvert AH, Davison R, Golding BT, Huang B, Loughlin PJ, Newell DR, Smith PG, Griffin RJ. Curtin NJ, et al. Among authors: golding bt. J Med Chem. 2004 Sep 23;47(20):4905-22. doi: 10.1021/jm040772w. J Med Chem. 2004. PMID: 15369395
Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.
Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Saravanan K, et al. Among authors: golding bt. J Med Chem. 2011 Mar 24;54(6):1847-59. doi: 10.1021/jm101493z. Epub 2011 Mar 2. J Med Chem. 2011. PMID: 21366300
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP).
Barlow HC, Bowman KJ, Curtin NJ, Calvert AH, Golding BT, Huang B, Loughlin PJ, Newell DR, Smith PG, Griffin RJ. Barlow HC, et al. Among authors: golding bt. Bioorg Med Chem Lett. 2000 Mar 20;10(6):585-9. doi: 10.1016/s0960-894x(00)00053-6. Bioorg Med Chem Lett. 2000. PMID: 10741559
Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR, Golding BT, Griffin RJ. Hardcastle IR, et al. Among authors: golding bt. Annu Rev Pharmacol Toxicol. 2002;42:325-48. doi: 10.1146/annurev.pharmtox.42.090601.125940. Annu Rev Pharmacol Toxicol. 2002. PMID: 11807175 Review.
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.
Hardcastle IR, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Källblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J. Hardcastle IR, et al. Among authors: golding bt. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1515-20. doi: 10.1016/j.bmcl.2004.12.061. Bioorg Med Chem Lett. 2005. PMID: 15713419
189 results